Clinical Trials Logo

Clinical Trial Summary

Corneal epithelial disruption, commonly termed "corneal staining" has been frequently associated with contact lens wear. Previous research has demonstrated higher levels of observed corneal staining when certain combinations of contact lenses and lens care products are used, particularly under daily wear regimens. B+L lenses made from Balafilcon (PureVision) have been associated with the highest rates of observed staining. Additionally, polyhexamethylene biguanide (PHMB) based lens care products, specifically B+L ReNu MultiPlus have been implicated in higher rates of staining. In general, many lenses constructed from newer, silicone hydrogel (SiHy) materials appear more susceptible to increased rates and amounts of corneal staining.

Although the clinical significance of staining is debated, most clinicians agree that less staining is preferable to greater amounts of staining. Advances in understanding as well as the specifics of lens care product formulation ideally will have resulted in design of newer products that minimize corneal staining and maximize product performance. This study will examine rates of corneal staining using B+L's recently introduced lens care product: BioTrue with the B+L PureVision lens which has previously been associated with the highest levels of staining.


Clinical Trial Description

Corneal epithelial disruption, commonly termed "corneal staining" has been frequently associated with contact lens wear. Previous research has demonstrated higher levels of observed corneal staining when certain combinations of contact lenses and lens care products are used, particularly under daily wear regimens. B+L lenses made from Balafilcon (PureVision) have been associated with the highest rates of observed staining. Additionally, polyhexamethylene biguanide (PHMB) based lens care products, specifically B+L ReNu MultiPlus have been implicated in higher rates of staining. In general, many lenses constructed from newer, silicone hydrogel (SiHy) materials appear more susceptible to increased rates and amounts of corneal staining.

Although the clinical significance of staining is debated, most clinicians agree that less staining is preferable to greater amounts of staining. Advances in understanding as well as the specifics of lens care product formulation ideally will have resulted in design of newer products that minimize corneal staining and maximize product performance. This study will examine rates of corneal staining using B+L's recently introduced lens care product: BioTrue with the B+L PureVision lens which has previously been associated with the highest levels of staining.

This pilot study is intended to assess the presence of corneal staining among patients who are using BioTrue solution ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Related Conditions & MeSH terms


NCT number NCT01268306
Study type Interventional
Source Epstein, Arthur B., OD, FAAO
Contact
Status Completed
Phase Phase 4
Start date October 2010
Completion date December 2010

See also
  Status Clinical Trial Phase
Completed NCT00513734 - A Comparison of Hydrogel Dressings and Ocular Lubricants in the Prevention on Corneal Damage in the Critically Ill N/A
Enrolling by invitation NCT03436576 - Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye Phase 3
Recruiting NCT06229379 - The Effects of a Large Language Model on Clinical Questioning Skills N/A
Completed NCT01028027 - Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis Phase 3
Recruiting NCT05432336 - Complex Ocular Infection, Optimization of Microbiological Diagnosis
Completed NCT04169061 - Impact of Acthar on Everyday Life of Participants With Severe Keratitis Phase 4
Completed NCT03237936 - Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis Phase 4
Completed NCT00001734 - Screening for NEI Clinical Studies N/A
Recruiting NCT05255107 - Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers Phase 2/Phase 3
Recruiting NCT05255016 - Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers Phase 2/Phase 3
Terminated NCT05250583 - Use of a Biological Lens of Amniotic Membrane (LV-Visio-AMTRIX) in the Treatment of Treatment-Resistant Keratitis Phase 2
Recruiting NCT02865876 - Effectiveness of Corneal Accelerated Crosslinking for Infectious Keratitis Phase 3
Terminated NCT02116062 - Robotic Surgery of the Ocular Surface N/A
Recruiting NCT00838422 - Reliability of Pachymetry Measurement With FD-oCT, ORA, Confoscan 4 and Ultrasound N/A
Completed NCT00949468 - Microbiological Keratitis in a Countryside City of Brazil N/A
Completed NCT03586505 - Tolerance to Light for Patients Suffering From Keratitis N/A
Recruiting NCT04420962 - Automated Quantitative Ulcer Analysis Study
Completed NCT02186431 - Contact Lenses and Infiltrative Keratitis N/A
Completed NCT05538793 - Deep Learning for the Discrimination Among Different Types of Keratits: a Nationwide Study
Not yet recruiting NCT05689996 - Ozone-based Eye Drops as Adjuvant Therapy in Microbial Keratitis Phase 3